Integumen PLC - Partners with Avacta for novel SARS-CoV-2 sensors
AIM share code: SKIN
13 July 2020
("Integumen" or "Company")
Integumen partners with
Collaboration offers hotspot detection monitoring in wastewater
Integumen has signed a Material Transfer Agreement ("MTA") with
The MTA formalises Integumen's access to Avacta's Affimers to be coated onto Integumen's proprietary silicon wafer nano-photonic surfaces. Integumen, who are already well advanced with the miniaturisation of the virus detection prototype, will make use of up to six Affimers to be tested at the Company's
Upon successful completion of the evaluation, Integumen and the Avacta will enter into a supply agreement for the supply of Affimers into Integumen's sensors which will initially be integrated and retrofitted into Modern Water plc's Microtox water contamination system units to detect the coronavirus. The Microtox system, which can detect the presence of contaminating bacteria, virus and toxins but not yet identify them, is distributed by Modern Water and has a global footprint of over 3,000 installations.
"We are delighted to be collaborating with Avacta, adding their highly specific and robust Affimer reagent to our real-time alert arsenal of pathogen capture devices of the COVID-19 virus in sewage. The global pandemic has highlighted wastewater as an early warning hotspot detection opportunity and the inclusion of Affimer reagents with our sensors adds an already established method of capturing the virus to an already established pathogen alert system1."
"I am very pleased to be entering into this collaboration with Integumen which holds substantial commercial potential for an Affimer-based consumable SARS-COV-2 detector unit to retrofit into the large global installed based of Microtox systems. Affimer reagents are ideal for applications such as this not only because of their sensitivity and specificity but also because of their robustness which is essential when being deployed in real-world situations like real-time waste-water analysis.
With the spread of COVID-19 continuing to accelerate globally, we are proud to work with partners like Integumen to provide our Affimer reagents for development on a range of platforms to combat the pandemic. This collaboration has the potential to deliver a product that will play a crucial role in the early detection of COVID-19 hotspots around the world.
I look forward to updating the market very soon on progress with Integumen and other COVID-19 related programmes"
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
| || |
+44 (0) 7340 055 648
| || |
+44 (0) 113 370 8974
| || || |
+44 (0) 20 3657 0050
Integumen is a scientific research and AI-as-a-Service company focused on production and analysis of bacteria, virus and toxins utilising artificial intelligent data analytics in regulatory technology, from scientifically proving the impact of skincare product claims on skin microbiome for top 10 global cosmetic company clients to remotely detecting water contamination in real-time.
Avacta is developing novel cancer immunotherapies combining its two proprietary platforms - Affimer® biotherapeutics and pre|CISION™ tumour targeted chemotherapy. With this approach, Avacta aims to address the lack of a durable response to current immunotherapies experienced by most patients. Avacta's therapeutics development activities are based in
Avacta benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby,
The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of
Avacta's pre|CISION targeted chemotherapy platform, releases active chemotherapy only in the tumour, thereby limiting systemic exposure and damage to healthy tissues, and thereby improving the overall safety and therapeutic potential of these powerful anti-cancer treatments.
By combining these two platforms Avacta is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta expects to take its first drug, a pre|CISION targeted form of the standard-of-care Doxorubicin, into the clinic later in 2020 or early 2021.
Avacta has established drug development partnerships with pharma and biotech, including with
Avacta diagnostics business unit works with partners world-wide to develop Affimers for evaluation by those third parties with the objective of establishing royalty bearing license deals. Avacta is also developing a small in-house pipeline of Affimer-based diagnostic assays for licensing. (Source :
About Modern Water
Modern Water was established in 2006 to develop and commercialise water recovery technologies to counter water crisis problems arising from climate change and a growing global population. Having invested
1 Remote Automated Water Test (RAWTest) incorporating artificial intelligence (AI) develop in a consortium partly funded by the
This information is provided by RNS, the news service of the
Quick facts: Integumen
Market Cap: £57.09 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE